Summary

The leading business intelligence provider, has released its latest research “Ribonucleic Acid (RNA) Therapeutics - Strong Potential to Address Unmet Needs in Pharma”, which provides insights into the unmet needs in the pharmaceutical and healthcare market and potential segments where RNA therapies can prove to be useful. This pharma report also delves deep into the market potential that RNA therapies hold in the future. Further, it provides insights into the R&D pipeline and the promising drugs. The study elucidates the current competitive landscape of the RNA therapeutics market. Finally, the report deals with key trend analysis on mergers and acquisitions, and licensing agreements involving RNA therapies.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Scope

The scope of this report includes:
- Detailed market characterization including evaluation of market potential, annual cost of therapy and treatment usage patterns
- Key technologies that have created significant impact on research and development of RNA therapeutics
- Key factors that can drive the RNA therapeutics market potential
- Key risks and issues associated with various RNA therapies
- Competitive landscape of RNA therapeutics market. The key companies studied in this report are Antisense Pharma GmbH, Lorus Therapeutics, Isis Pharmaceuticals, Alfacell Corporation, Genta Incorporated, Atlantic Healthcare, Alnylam, OPKO, Oxford BioMedica, Dicerna Pharmaceuticals, Silence Therapeutics plc, Cequent Pharmaceuticals, Inc and Santaris Pharma.
- Key M&A activities and licensing agreements that have taken place between 2008 and 2009 in the RNA therapeutics market.

Reasons to buy

The report will aid business development and marketing executives in strategizing their product launches and help venture capitalists to identify promising small and medium sized enterprises. It will allow you to
- Build effective strategies to launch pipeline products by identifying potential geographies
- Exploit in-licensing and out-licensing opportunities by identifying products that will fill the portfolio gaps
- Develop key strategic initiatives by studying the key strategies of top competitors
- Identify potential SME companies that hold a lot of promise
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first in class molecules with more efficiency and better safety"

1
1 3
1.1 List of Tables 6
1.2 List of Figures 7
2 RNA Therapeutics: Introduction 8
2.1 GBI Research Report Guidance 8
3 RNA Therapeutics – Introduction to Ribonucleic Acid (RNA) 9
3.1 What is RNA Therapy? 9
3.1.1 RNA is the Key for Protein Synthesis 9
3.2 Blocking Translation of mRNA Inhibits Protein Biosynthesis, the Key for Cell Proliferation 10
3.3 Role of RNA in Pharmaceutical Industry 10
3.3.1 Upstream Action of RNA Therapies Make them more effective Than the Existing Biologic Therapies 10
4 RNA Therapeutics – Overview on RNA Technology 12
4.1 Antisense RNA 12
4.1.1 Therapeutic Objective 12
4.1.2 Issues with Antisense RNA Therapy 12
4.1.3 Solutions Developed to Overcome Issues 14
4.2 RNA Interference Technology 15
4.2.1 siRNA 15
4.2.2 Micro RNA 16
4.2.3 Issues with Interfering RNA Therapy 17
4.2.4 Soultions Developed to Overcome Issues 19
4.3 RNA Therapies Are Expected To Create Significant Impact on the Current Therapies After They Enter the Market 22
4.3.1 Current Therapies in the Market Are Expected to Witness Strong Competition from RNA Therapies Once They Enter the Market 22
4.3.2 RNA Therapies Have Created a Significant Impact on Major Funding Institutions Such As Venture Capitalist Firms and Private Equity Firms 22
4.3.3 The Impact of RNA Therapies on Patients Is Expected To Grow Gradually Since Patients Would Switch Over Only After RNA Therapies Pass through Proof-Of-Concept Studies 22
4.3.4 RNA Therapeutics Has Already Made a Significant Impact on Large Pharmaceutical and Biotech Companies 23
4.4 Key Challenges Such As Lack of Effective Delivery Systems are Holding Back RNA Therapies from Entering the Market 23
5 RNA Therapeutics – Market Characterization 24
5.1 Market Potential 24
5.2 Target Sales Volume 25
5.3 Annual Cost of Therapy 26
5.4 Technology Adoption Framework 27
5.4.1 RNA Technology has the potential to meet Unmet-needs in Major Diseases 27
5.4.2 RNA technology Failed in Proof-of-concept Studies 27
5.4.3 Lack of awareness among patients as well as physicians is embracing the adoption of RNA Technology 28
5.4.4 RNA therapies, launched till now, failed to pass through proof-of-concept studies 28
5.5 RNA Therapeutics Market Drivers 28
5.5.1 Dual Mechanism of Action is the Major Factor Driving RNA Therapeutics Market Potential 28
5.5.2 Failure of Conventional Therapies in Curing Chronic Diseases has Created High-unmet Needs 29
5.5.3 Major Break-through Technologies in RNA Research and Development Opened-up New Markets 30
5.5.4 Increased Funding on RNA Research by Major Countries such as the US and Europe 30
5.6 RNA Therapeutics Market Restraints 30
5.6.1 Many RNA Therapies are Failing at Phase III Clinical Development 30
5.6.2 The Characteristics of RNA Structure make them Vulnerable to Human Enzymes 31
5.6.3 Lack of Effective Delivery Technologies That can Deliver RNA therapies to the Target Site are making RNA Therapies Ineffective 31
5.6.4 RNA therapies can cause potential side-effects and off-target effects 31
6 RNA Therapeutics – Market Description 32
6.1 SWOT Analysis 32
6.1.1 RNA Therapies Hold a Competitive Edge over Conventional Therapies Due to Their Gene Silencing Ability 32
6.1.2 Although RNA Therapies Have the Potential to Cure Diseases, Few Drawbacks Such As Instability and Off-targets are Holding Them from Displaying Desired Efficacy Levels 32
6.1.3 Abundant Opportunities in Terms of Unmet Needs Exist for RNA Therapies in Chronic disease Conditions Associated with Genetic Mutations and Protein Overexpression 33
6.1.4 Similar to RNA Therapies, Other Treatments such as Stem Cell Therapies Are Also in Research and Development, and These Therapies Can Pose a Threat to RNA Therapeutics Market Potential 33
6.2 Porters Five Forces Analysis on RNA Therapeutics 33
6.2.1 Threat of Substitutes 33
6.2.2 Threat of Potential Entrants 34
6.2.3 Bargaining Power of Suppliers 34
6.2.4 Bargaining Power of Buyers 34
6.3 PEST Analysis 35
6.3.1 The US 35
6.3.2 The Top five Countries in Europe 36
6.3.3 Japan 37
6.4 Funding 38
6.4.1 US 38
6.4.2 Europe 39
7 RNA Therapeutics – Competitive Landscape 40
7.1 Key Players 41
7.1.1 Antisense Pharma GmbH 41
7.1.2 Lorus Therapeutics 42
7.1.3 Isis Pharmaceuticals 43
7.1.4 Alfacell Corporation 44
7.1.5 Genta Incorporated 45
7.1.6 Atlantic Healthcare 46
7.1.7 Alnylam 46
7.1.8 OPKO 50
7.2 Promising Companies Developing RNAi under Collaborations with major Companies 51
7.2.1 Oxford BioMedica 51
7.2.2 Dicerna Pharmaceuticals 53
7.2.3 Silence Therapeutics plc 53
7.2.4 Cequent Pharmaceuticals, Inc 54
7.2.5 SantarisPharma A/S 54
8 RNA Therapeutics – R&D Pipeline Analysis 56
8.1 Strategic Pipeline Assessment 56
8.2 Profiles of Key Late-Stage Drugs 59
8.2.1 Mipomersen 59
8.2.2 Bevasiranib 59
8.2.3 LOR-2040 60
8.2.4 Genasense 60
8.2.5 Trovax 61
8.2.6 Trabedersen 61
8.2.7 Onconase 62
8.2.8 Alicaforsen 62
8.3 Insights into Most Promising Drugs 63
8.3.1 Mipomersen 63
8.3.2 LOR-2040 63
8.3.3 Genasense 64
8.3.4 ProSavin 65
8.3.5 Trovax 66
8.3.6 Trabedersen 66
8.3.7 Onconase 67
8.3.8 Alicaforsen 68
9 RNA Therapeutics – M&A Landscape 70
9.1 Big Pharmaceutical Companies Relentlessly Attempting to Unlock RNA therapy Potential 70
9.2 Influx of Huge Venture Capitalist Funding into Small and Medium Biotech Companies Venturing into RNA Therapeutics Development 71
9.2.1 Dicerna Pharmaceuticals 71
9.2.2 Cequent Pharmaceuticals 71
9.2.3 Prosensa 71
9.2.4 Cylene Pharmaceuticals 71
9.3 High Value Collaborations involving RNA Therapies 71
9.3.1 ISIS Pharmaceuticals 71
9.3.2 Alnylam 72
9.3.3 Silence Therapeutics and AstraZeneca 72
9.3.4 Santaris Pharma and Wyeth Pharmaceuticals 72
9.4 Large Pharmaceutical and Biotechnology companies are vying for major acquisitions in the RNA Therapeutics Market 72
9.4.1 Thermo Fisher Scientific and Open Biosystems 72
9.4.2 Roche and Mirus Bio 72
9.5 R&D Licensing Agreements 73
9.5.1 Deals by Phase 73
9.5.2 Deals by Geography 73
9.5.3 Deals by Licensing Type 74
9.5.4 Deals by Value ($) 75
9.5.5 Discovery/Development 75
9.5.6 Preclinical 80
9.5.7 Phase I 81
9.5.8 Phase II 81
9.5.9 Phase III 82
10 RNA Therapeutics: Appendix 83
10.1 Market Definitions 83
10.2 Abbreviations 83
10.3 Research Methodology 84
10.3.1 Coverage 85
10.3.2 Secondary Research 85
10.3.3 Primary Research 86
10.3.4 Forecasts 86
10.3.5 Expert Panel Validation 88
10.4 Contact Us 89
10.5 Disclaimer 89
10.6 Sources 89

1.1 List of Tables
Table 1: RNA Therapeutics, Global, siRNA and shRNA Delivery Options, November 2009 20
Table 2: RNA Therapeutics, Global, Market Potential ($ m), 2005-2015 25
Table 3: RNA Therapeutics, Global, Diagnosis Population, 2011-2015 26
Table 4: RNA Therapeutics, Global, Antisense Pharma R&D Pipeline, November 2009 42
Table 5: RNA Therapeutics, Global, Lorus Therapeutics R&D Pipeline, November 2009 43
Table 6: RNA Therapeutics, Global, Isis Pharmaceuticals, R&D Pipeline, November 2009 44
Table 7: RNA Therapeutics, Global, Alfacell Corporation, R&D Pipeline, November 2009 45
Table 8: RNA Therapeutics, Global, Genta Inc., R&D Pipeline, November 2009 45
Table 9: RNA Therapeutics, Global, Alnylam, InterfeRx Licensing Agreements, November 2009 47
Table 10: RNA Therapeutics, Global, Alnylam, Licensing Agreements, November 2009 48
Table 11: RNA Therapeutics, Global, OPKO, Bevasirnanib Development History, November 2009 51
Table 12: RNA Therapeutics, Global, OPKO, Antisense Drugs Pipeline, November 2009 51
Table 13: RNA Therapeutics, Global, Oxford BioMedica, R&D Pipeline, November 20